An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease von Rieder, F., Bettenworth, D., Ma, C., Parker, C. E., Williamson, L. A., Nelson, S. A., van Assche, G., Di Sabatino, A., Bouhnik, Y., Stidham, R. W., Dignass, A., Rogler, G., Taylor, S. A., Stoker, J., Rimola, J., Baker, M. E., Fletcher, J. G., Panes, J., Sandborn, W. J., Feagan, B. G., Jairath, V.

Volltext

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms von Ordás, I, Mould, D R, Feagan, B G, Sandborn, W J

Volltext

Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort von Gower-Rousseau, Corinne, Sarter, Hélène, Savoye, Guillaume, Tavernier, Noémie, Fumery, Mathurin, Sandborn, William J, Feagan, Brian G, Duhamel, Alain, Guillon-Dellac, Nathalie, Colombel, Jean-Frédéric, Peyrin-Biroulet, Laurent

Volltext

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy von Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.

Volltext

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials von Jairath, V., Khanna, R., Zou, G. Y., Stitt, L., Mosli, M., Vandervoort, M. K., D'Haens, G., Sandborn, W. J., Feagan, B. G., Levesque, B. G.

Volltext

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity von Khanna, R., Zou, G., D'Haens, G., Feagan, B. G., Sandborn, W. J., Vandervoort, M. K., Rolleri, R. L., Bortey, E., Paterson, C., Forbes, W. P., Levesque, B. G.

Volltext

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease von Rosario, M., Dirks, N. L., Gastonguay, M. R., Fasanmade, A. A., Wyant, T., Parikh, A., Sandborn, W. J., Feagan, B. G., Reinisch, W., Fox, I.

Volltext

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials von Vuitton, L, Marteau, P, Sandborn, W J, Levesque, B G, Feagan, B, Vermeire, S, Danese, S, D'Haens, G, Lowenberg, M, Khanna, R, Fiorino, G, Travis, S, Mary, J Y, Peyrin-Biroulet, L

Volltext

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease von Levesque, B. G., Greenberg, G. R., Zou, G., Sandborn, W. J., Singh, S., Hauenstein, S., Ohrmund, L., Wong, C. J., Stitt, L. W., Shackelton, L. M., King, D., Lockton, S., Ducharme, J., Feagan, B. G.

Volltext

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial von Sandborn, W J, Feagan, B G, Radford-Smith, G, Kovacs, A, Enns, R, Innes, A, Patel, J

Volltext

Editorial: the impact of the placebo effect in Crohn's disease – author's reply von Jairath, V., Feagan, B. G.

Volltext

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease von Khanna, R., Sattin, B. D., Afif, W., Benchimol, E. I., Bernard, E.‐J., Bitton, A., Bressler, B., Fedorak, R. N., Ghosh, S., Greenberg, G. R., Marshall, J. K., Panaccione, R., Seidman, E. G., Silverberg, M. S., Steinhart, A. H., Sy, R., Van Assche, G., Walters, T. D., Sandborn, W. J., Feagan, B. G.

Volltext

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease von Vande Casteele, N., Feagan, B. G., Vermeire, S., Yassine, M., Coarse, J., Kosutic, G., Sandborn, W. J.

Volltext

Review article: dose optimisation of infliximab for acute severe ulcerative colitis von Hindryckx, P., Novak, G., Vande Casteele, N., Laukens, D., Parker, C., Shackelton, L. M, Narula, N., Khanna, R., Dulai, P., Levesque, B. G, Sandborn, W. J, D'Haens, G., Feagan, B. G., Jairath, V.

Volltext

Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease von Ma, C., Dutton, S. J., Cipriano, L. E., Singh, S., Parker, C. E., Nguyen, T. M., Guizzetti, L., Gregor, J. C., Chande, N., Hindryckx, P., Feagan, B. G., Jairath, V.

Volltext

Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission von SANDBORN, W. J., FEAGAN, B. G., LICHTENSTEIN, G. R.

Volltext

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease von Feagan, B. G., Sandborn, W. J., D'Haens, G., Lee, S. D., Allez, M., Fedorak, R. N., Seidler, U., Vermeire, S., Lawrance, I. C., Maroney, A. C., Jurgensen, C. H., Heath, A., Chang, D. J.

Volltext

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial von Feagan, B. G., Patel, H., Colombel, J.‐F., Rubin, D. T., James, A., Mody, R., Lasch, K.

Volltext

Editorial: aminosalicylates in Crohn's disease—prevalence, risks, costs and time to reassess? Authors’ reply von Jairath, V., Ma, C., Feagan, B.

Volltext

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis von Rutgeerts, Paul, Sandborn, William J, Feagan, Brian G, Reinisch, Walter, Olson, Allan, Johanns, Jewel, Travers, Suzanne, Rachmilewitz, Daniel, Hanauer, Stephen B, Lichtenstein, Gary R, de Villiers, Willem J.S, Present, Daniel, Sands, Bruce E, Colombel, Jean Frédéric

Volltext